PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,771.50
Bid: 1,771.00
Ask: 1,771.50
Change: -12.00 (-0.67%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-U.S. tax hike less likely: a boon for Europe Inc too

Thu, 05th Nov 2020 10:08

* European shares open higher led by tech

* Strong Q3 earnings reports also help

* Bank of England ramps up stimulus

* Wall Street futures point to more gains
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

U.S. TAX HIKE LESS LIKELY: A BOON FOR EUROPE INC TOO (0957 GMT)

A gridlock in Washington with Biden president and Republicans retaining the Senate is a
scenario that's becoming more likely and equity investors are starting to appreciate the lower
likelihood of business unfriendly policy.

And the possible benefits for corporates, especially on the tax front, are going to be felt
on both sides of the pond.

"President Trump cut the U.S. corporation tax rate from 35% to 21%. The Democrats were
intending to raise it back to 28%. That prospect now seems less likely, which should help U.S.
equities," say Citi strategists.

"It should also boost non-US companies with significant US businesses. Their relative
performance has flat-lined recently," they added.

Several shares in European companies with big presence in the U.S. are doing relatively well
since it emerged that Trump was doing better than expected by the polls.

In the snapshot you can see today's price moves of a basket of European stocks with high
revenue exposure to North America. The basket, which includes names such as Deutsche Telekom
, UBS, Roche and National Grid, is courtesy of Citi.

(Danilo Masoni)

*****

OPENING SNAPSHOT: STRONG Q3, TECH RALLY AND MORE UK STIMULUS (0854 GMT)

European bourses are well in positive territory supported by a batch of positive Q3 results
and more stimulus in the UK as the country starts a second national lockdown.

The pan-European STOXX 600 index is up 0.8% to its highest level since Oct. 20,
with the tech sector leading the gains, up 2.5%.

Britain's blue chips are up 0.3% after the Bank of England increased its already
huge bond-buying stimulus by a bigger-than-expected 150 billion pounds to 895 billion pounds.
The BoE kept the bank rate at 0.1%.

In terms of single companies, Milan-listed Tenaris is set for its best day in 9
years after reporting strong Q3 results, it was last up more than 11%.

(Joice Alves)

*****

ON THE RADAR: BANKS Q3, ARCELORMITTAL, SAINSBURY (0746 GMT)

Looking at futures, it seems like it is going to be a start of the day in the black for
European bourses in a data heavy morning, which also sees investors having to digest a slew of
earnings results.

There is a mixed batch of banking Q3 results with France's third-biggest listed bank Societe
Generale swinging back to profit, as its equity trading business continued to recover
from a weak start to the year; and Italy's second-biggest bank UniCredit posted much
higher than expected net profit as Europe emerged from lockdowns.

In the meantime, Germany's Commerzbank swung to a Q3 loss, as the lender undergoes
a restructuring.

ING Groep, the largest Dutch bank, reported lower than expected pre-tax profit of
1.20 billion euros on declining interest income amid the coronavirus pandemic and said it
intends to cut 1,000 jobs.

British supermarket group Sainsbury also said it could cut 3,500 jobs in a
restructuring.

On a brighter note, ArcelorMittal, the world's largest steelmaker, reported Q3 core
profit above expectations as the easing of lockdowns led to improved demand.
German broadcaster ProSiebenSat.1 Media returned to profit, and reinstated its FY
guidance. Its shares rose 5.7% in premarket trade.

HeidelbergCement, the world's No.2 cement maker, posted a 13% increase in Q3 core
profit, as cost cuts helped it to shrug off the impact of the pandemic and forecast higher
earnings for 2020.

Siemens Gamesa keeps profit target as Q4 uptick fails to stave off loss.

British insurer RSA's underwriting profit rose strongly in the first nine months of
2020 due to improvements the company made to its underwriting strategy.

German reinsurance group Munich Re's net profit declined 77% to 199 million euros
in Q3.

Staying in Germany, specialty chemicals maker Lanxess narrowed its 2020 core
profit outlook range after the coronavirus pandemic, saying it was seeing a pick up in the auto
industry, with China and the U.S. also providing positive stimuli.

While Lufthansa said it booked a net loss of 2 billion euros in Q3.

Sunrise Communications announced plans to boost its 2020 dividend to 4.55 and 4.65
Swiss francs per share, from 4.4 francs, ahead of the Swiss telecommunications firm's takeover
by Liberty Global that will lead to its delisting.

(Joice Alves)

*****

MORNING CALL: STILL NO U.S. PRESIDENT (0638 GMT)

Futures are pointing to gains for European bourses this morning mirroring Asian shares,
which climbed on the prospect that a gridlock in the U.S. Congress will give a boost to some
industries.

So far, the count shows that Democratic challenger Joe Biden narrowly ahead in key states,
but the risk of a prolonged contested election remains.

Back in Europe, it will be a data heavy morning with EZ and UK PMI data due.

The Bank of England's November monetary policy decision is also on schedule. The Telegraph
newspaper reported that the central bank is considering a move into negative interest rates.

(Joice Alves)

*****

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.